Évangéline Pillebout

5.3k citations

65 papers · 2.5k indexed · h-index 25

Nephrology top 0.5%
Pulmonary and Respiratory Medicine top 2%
Rheumatology top 2%
Surgery top 10%
Molecular Biology

Co-authors: Dominique Nochy Gary S. Hill Corinne Alberti Éric Thervet Philippe Vanhille Denis Glotz Gérard Friedlander Fabiola Terzi
Topics: Renal Diseases and Glomerulopathies (27 papers)Vasculitis and related conditions (26 papers)Urticaria and Related Conditions (18 papers)
Cited by: Nephrology Transplantation Rheumatology
Journals: Journal of Clinical InvestigationSHILAP Revista de lepidopterologíaPLoS ONE
Partner nations: France United Kingdom United States

In The Last Decade

Évangéline Pillebout

57 papers receiving 2.4k citations

Peers

Countries citing papers authored by Évangéline Pillebout

Since Specialization

Citations

This map shows the geographic impact of Évangéline Pillebout's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Évangéline Pillebout with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Évangéline Pillebout more than expected).

Fields of papers citing papers by Évangéline Pillebout

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Évangéline Pillebout. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Évangéline Pillebout. The network helps show where Évangéline Pillebout may publish in the future.

Co-authorship network of co-authors of Évangéline Pillebout

This figure shows the co-authorship network connecting the top 25 collaborators of Évangéline Pillebout. A scholar is included among the top collaborators of Évangéline Pillebout based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Évangéline Pillebout. Évangéline Pillebout is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment strategies and outcomes in adult relapsing or refractory cutaneous IgA Vasculitis: A multicenter retrospective cohort study 2025 ·Seminars in Arthritis and Rheumatism ·(unknown),T. Mahévas,(unknown),Guillaume Moulis,(unknown),Patricia Senet,Évangéline Pillebout,Xavier Puéchal,Cécile‐Audrey Durel,Alexandra Audemard‐Verger,Vincent Grobost,M. Jachiet,Benjamin Terrier	0
2	Multicentre, randomised, economic evaluation of a web-based interactive education platform, simple or enhanced, for patients with end-stage renal disease: the PIC-R trial protocol 2022 ·BMJ Open ·Évangéline Pillebout,Isabelle Durand‐Zaleski,(unknown),Lionel Perrier,Clément de Chaisemartin,(unknown),Luc Behaghel,Lise Rochaix	0
3	IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients 2022 ·The Journal of Rheumatology ·(unknown),(unknown),(unknown),(unknown),(unknown),Kévin Didier,C. Paul,É. Liozon,(unknown),G. Richard-Colmant,Benjamin Terrier,Guillaume Moulis,Margaux Lafaurie,Évangéline Pillebout,F. Maillot,Alexandra Audemard‐Verger	5
4	IgA vasculitis 2021 ·Seminars in Immunopathology ·Évangéline Pillebout,Cord Sunderkötter	80
5	Spondyloarthritis-Associated IgA Nephropathy 2020 ·Kidney International Reports ·N. Champtiaux,Frédéric Lioté,Khalil El Karoui,Cécile Vigneau,Corinne Miceli‐Richard,Émilie Cornec-Le Gall,Philippe Rémy,Gabriel Choukroun,Fádi Fakhouri,Cyril Garrouste,(unknown),Évangéline Pillebout,Thierry Lobbedez,Vincent Vuiblet,Alain Wynckel,(unknown),Éric Toussirot,Éric Thervet,Marion Rabant,Alexandre Karras	11
6	Vascularite à IgA (purpura rhumatoïde) l’adulte 2019 ·Néphrologie & Thérapeutique ·Évangéline Pillebout	3
7	15th International Symposium on IgANephropathy – IIgANN 2018, Buenos Aires, September 27-29, 2018: Summaries 2018 ·Kidney Diseases ·Sean Barbour,(unknown),Daniel Cattran,Mark Haas,James Mirocha,Évangéline Pillebout,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	1
8	Biomarkers of IgA vasculitis nephritis in children 2017 ·PLoS ONE ·Évangéline Pillebout,Agnès Jamin,(unknown),P Housset,(unknown),Virginia Sauvaget,Denis Viglietti,Georges Deschênes,Renato C. Monteiro,Laureline Berthelot,(unknown)	75
9	Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers 2016 ·Joint Bone Spine ·Pierre‐Antoine Juge,Marie‐Elise Truchetet,Évangéline Pillebout,Sébastien Ottaviani,Cécile Vigneau,(unknown),Divi Cornec,Tristan Pascart,Renaud Snanoudj,(unknown),Émilie Cornec-Le Gall,Thierry Schaeverbeke,Alain Saraux,Philippe Dieudé,René‐Marc Flipo,Pascal Richette,Frédéric Lioté,Thomas Bardin,Gérard Chalès,Hang‐Korng Ea	34
10	Gluten exacerbates IgA nephropathy in humanized mice through gliadin–CD89 interaction 2015 ·Kidney International ·Christina Papista,Sébastian Lechner,Sanae Ben Mkaddem,(unknown),Lilia Abbad,Julie Bex-Coudrat,Évangéline Pillebout,Jonathan Chemouny,Mathieu Jablonski,Martin Flamant,Éric Daugas,François Vrtovsnik,Minas Yiangou,Laureline Berthelot,Renato C. Monteiro	87
11	Purpura rhumatoïde de l’adulte 2014 ·La Revue de Médecine Interne ·Évangéline Pillebout,J. Vérine	19
12	Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: Effects on long-term renal function after liver transplantation 2012 ·Journal of Hepatology ·Yvon Calmus,Filoména Conti,Philippe Cluzel,Gary S. Hill,Corinne Antoine,Olivier Scatton,Olivier Soubrane,Denis Glotz,Évangéline Pillebout,Dominique Nochy	25
13	Severe Acute Renal Failure in an HIV-Infected Patient After Only 2 Weeks of Tenofovir-Based Antiretroviral Therapy 2011 ·AIDS Patient Care and STDs ·Juliette Pavie,Anne Scemla,Marie‐Anne Bouldouyre,Évangéline Pillebout,Jérôme Verine,Jean‐Michel Molina	7
14	Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report 2011 ·Nephrology Dialysis Transplantation ·Évangéline Pillebout,(unknown),L. Fardet,M. Rybojad,J. Vérine,Denis Glotz	40
15	TGF-α Mediates Genetic Susceptibility to Chronic Kidney Disease 2010 ·Journal of the American Society of Nephrology ·Denise Laouari,Martine Burtin,(unknown),(unknown),Évangéline Pillebout,Xavier Montagutelli,Gérard Friedlander,Fabiola Terzi	43
16	Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura 2010 ·Kidney International ·Évangéline Pillebout,Corinne Alberti,Loı̈c Guillevin,(unknown),Éric Thervet,(unknown)	98
17	Renal Transplantation in HIV‐Infected Patients: The Paris Experience 2010 ·American Journal of Transplantation ·Maxime Touzot,Évangéline Pillebout,Marie Matignon,Leïla Tricot,J.-P. Viard,Éric Rondeau,Christophe Legendre,Denis Glotz,Michel Delahousse,Philippe Lang,M.N. Peraldi	69
18	Purpura rhumatoïde 2009 ·Néphrologie & Thérapeutique ·Évangéline Pillebout,Dominique Nochy,É. Thervet	13
19	Purpura rhumatoïde de l’adulte 2008 ·La Presse Médicale ·Évangéline Pillebout	9
20	Clinical Operational Tolerance after Kidney Transplantation 2006 ·American Journal of Transplantation ·(unknown),Magali Giral,Philippe Moreau,(unknown),Christophe Legendre,C. Noël,Évangéline Pillebout,Sophie Brouard,Jean‐Paul Soulillou	138

About Évangéline Pillebout

Évangéline Pillebout is a scholar working on Nephrology, Transplantation and Rheumatology, having authored 65 papers that have together received 2.5k indexed citations. Recurring topics across this work include Renal Diseases and Glomerulopathies (27 papers), Vasculitis and related conditions (26 papers) and Urticaria and Related Conditions (18 papers). The work is most often cited by research in Nephrology (1.1k citations), Transplantation (292 citations) and Rheumatology (516 citations). Évangéline Pillebout has collaborated with scholars based in France, United Kingdom and United States. Frequent co-authors include Dominique Nochy, Gary S. Hill, Corinne Alberti, Éric Thervet, Philippe Vanhille, Denis Glotz, Gérard Friedlander, Fabiola Terzi, Loı̈c Guillevin and Cord Sunderkötter. Their work appears in journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact